| Literature DB >> 30274203 |
Zhi-Hui Liu1,2,3, Tao Li4, Qing-Yu He5, Zheng Sun6,7,8, Yue Jiang9.
Abstract
The green alga Chlorella pyrenoidosa can accumulate lutein and chlorophyll under heterotrophic conditions. We propose that the mitochondrial respiratory electron transport chain (mRET) may be involved in this process. To verify this hypothesis, algal cells were treated with different mRET inhibitors. The biosynthesis of lutein and chlorophyll was found to be significantly stimulated by salicylhydroxamic acid (SHAM), whereas their contents substantially decreased after treatment with antimycin A and sodium azide (NaN₃). Proteomic studies revealed profound protein alterations related to the redox and energy states, and a network was proposed: The up-regulation of peroxiredoxin reduces oxidized glutathione (GSSG) to reduced glutathione (GSH); phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the conversion of oxaloacetic acid to phosphoenolpyruvate, and after entering the methylerythritol phosphate (MEP) pathway, 4-hydroxy-3-methylbut-2-en-1yl diphosphate synthase reduces 2-C-methyl-d-erythritol-2,4-cyclodiphosphate (ME-Cpp) to 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate (HMBPP), which is closely related to the synthesis of lutein; and coproporphyrinogen III oxidase and ChlI play important roles in the chlorophyll biosynthetic pathway. These results supported that for the heterotrophic C. pyrenoidosa, the signaling, oriented from mRET, may regulate the nuclear genes encoding the enzymes involved in photosynthetic pigment biosynthesis.Entities:
Keywords: energy metabolism; mitochondrial respiratory electron transport chain; mitochondrial retrograde regulation; proteomics; redox state
Mesh:
Substances:
Year: 2018 PMID: 30274203 PMCID: PMC6213193 DOI: 10.3390/md16100354
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Schematic diagram of the mitochondrial respiratory electron transport chain (mRET) and the action sites of inhibitors. Complex I, reduced nicotinamide adenine dinucleotide (NADH) coenzyme Q reductase; complex II, succinate dehydrogenase; UQ, ubiquinone; complex III, cytochrome bc1 complex; complex IV, cytochrome c oxidase; complex V, ATPase; AOX, alternative oxidase; Cyt c, cytochrome c; SHAM, salicylhydroxamic acid; CCCP, carbonyl cyanide m-chlorophenylhydrazone.
Variation in total biomass dry weight (g/L), lutein and chlorophyll contents (mg/g dry cell weight) following mitochondrial dysfunction.
| Inhibitors | Biomass (%) | Lutein (%) | Chl. a (%) | Chl. b (%) |
|---|---|---|---|---|
| Antimycin A (0.1 mM) | 59.5 ± 3.2 | 87.7 ± 3.5 | 73.2 ± 2.3 | 73.4 ± 2.5 |
| NaN3 (0.05 mM) | 68.9 ± 9.6 | 49.1 ± 1.4 | 38.9 ± 0.9 | 45.2 ± 1.7 |
| SHAM (0.5 mM) | 46.1 ± 8.6 | 156.9 ± 7.2 | 121.6 ± 3.6 | 136.1 ± 5.4 |
| CCCP (0.032 mM) | 42.7 ± 2.6 | 106.4 ± 3.2 | 104.5 ± 1.8 | 128.6 ± 2.8 |
| Rotenone (0.032 mM) | 41.4 ± 3.1 | 107.1 ± 1.6 | 103.1 ± 1.0 | 104.9 ± 0.4 |
The biomass and pigment contents are described as the percentage of the control. Data are expressed as averages ± S.D. of three independent measurements.
Figure 2Variation in energy and redox states in Chlorella pyrenoidosa after treatment with mRET inhibitors. (A) ATP/ADP; (B) GSH/GSSG; (C) NAD+/NADH. Data are expressed as averages ± S.D. of three independent measurements.
Figure 3Total proteins from mRET inhibitor-treated C. pyrenoidosa and the control. Lane 1, antimycin A treatment; lane 2, SHAM treatment; lane 3, NaN3 treatment; lane 4, control. Arrows: Representative bands in lanes 1–3 exhibiting significant difference with lane 4. The samples were loaded at the same protein concentration.
Figure 42-D gel images of total proteins from mRET inhibitor-treated C. pyrenoidosa and the control. The abundantly expressed spots, marked in the images with an arrow, were selected for identification. They are listed in Table 2 and Table 3. (A) control; (B) SHAM treatment; (C) antimycin A treatment; (D) NaN3 treatment. 2-DE was performed by loading 150 μg protein in a 13-cm non-linear immobilized pH gradient (IPG) strip with a pI range of 3–10, followed by separation on 12.5% SDS-PAGE after 1-D isoelectric focusing (IEF).
Up- and down-regulated proteins following SHAM, antimycin A and NaN3 treatment.
| Spot a | Protein Name b | Protein Function and Categorization c | Protein ID d | Species e | MW/ | Peptides f | Score g |
|---|---|---|---|---|---|---|---|
|
| |||||||
| D2 | Autophagy-related protein 3 | Protein transport, Protein fate (folding, modification, destination) | gi|307105862 |
| 35,252.9/4.42 | 1 | 35 |
| D3 | Adenylosuccinate synthetase | Purine nucleotide synthesis, Metabolism | gi|307108106 |
| 53,409.7/6.62 | 3 | 64 |
| D4 | Hypothetical protein CHLNCDRAFT_144859 | GMP synthase, Metabolism | gi|307108123 |
| 58,172.5/5.6 | 8 | 96 |
| D5 | Hypothetical protein CHLNCDRAFT_56182 | Adenylosuccinate synthetase, Metabolism | gi|307106668 |
| 64,272.6/5.81 | 4 | 59 |
| D6 | Phosphoserine aminotransferase | L-glutamate synthesis, Metabolism | gi|307109471 |
| 44,960.5/5.60 | 1 | 37 |
| D9 | Hypothetical protein CHLNCDRAFT_139931 | Alternative splicing factor SRp20/9G8, Transcription | gi|307103428 |
| 19,849.2/11.52 | 6 | 53 |
| D10 | Hypothetical protein CHLNCDRAFT_134964 | SWI-SNF chromatin remodeling complex, Snf 5 subunit, Transcription | gi|307106629 |
| 22,841.5/5.85 | 1 | 27 |
| D12 | Nitrite reductase | NO biosynthesis, Cell rescue, defense and virulence | gi|116265919 |
| 22,954.7/9.11 | 1 | 60 |
| D14 | Coproporphyrinogen III oxidase | Key enzyme in heme synthesis, Metabolism | gi|71082810 |
| 32,383/9.83 | 1 | 68 |
| D15 | Hypothetical protein CHLNCDRAFT_30336 | ABC transporter superfamily, lipid transport, Protein with binding function or cofactor requirement | gi|307109169 |
| 65,272.95/8.50 | 1 | 26 |
| D17 | Hypothetical protein CHLNCDRAFT_56437 | gi|307111670 |
| 63,615.5/6.45 | 1 | 41 | |
| D19 | Nitrite reductase | NO biosynthesis, Cell rescue, defense and virulence | gi|116265919 |
| 22,954.7/9.11 | 1 | 69 |
| D21 | Malate dehydrogenase | Synthesis of oxaloacetate, Energy | gi|307103202 |
| 35,063.6/8.2 | 6 | 104 |
| D22 | Hypothetical protein CHLNCDRAFT_57327 | Galactokinase activity, Protein with binding function or cofactor requirement | gi|307109337 |
| 55,429.4/5.97 | 10 | 66 |
| D25 | Phytochrome A | G-protein coupled photoreceptor activity, Transcription | P42500 |
| 125,653.3/6.16 | 14 | 54 |
| D30 | Hypothetical protein CHLNCDRAFT_58635 | Chaperonin complex component, TCP-1 eta subunit (CCT7), Protein fate (folding, modification, destination) | gi|307105118 |
| 61,530.4/6.25 | 1 | 28 |
| D36 | Hypothetical protein CHLNCDRAFT_56384 | UDP-glucose 4-epimerase/UDP-sulfoquinovose synthase, Protein with binding function or cofactor requirement | gi|307103315 |
| 39,120.5/6.53 | 1 | 77 |
| D37 | Hypothetical protein CHLNCDRAFT_49080 | Phosphoenolpyruvate carboxykinase activity | gi|307104333 |
| 49,051.4/5.69 | 6 | 70 |
| D39 | Hypothetical protein CHLNCDRAFT_31785 | 14-3-3 family, multifunctional chaperone, Protein with binding function or cofactor requirement | gi|307106152 |
| 29,385.8/4.96 | 2 | 77 |
| D40 | Hypothetical protein CHLNCDRAFT_34933 | Prolyl-tRNA aminoacylation, Protein with binding function or cofactor requirement | gi|307109063 |
| 33,163.8/6.56 | 2 | 83 |
| D45 | Hypothetical protein CHLNCDRAFT_14282 | Aconitase/homoaconitase | gi|307110485 |
| 11,454.9/5.88 | 3 | 53 |
| D46 | Expressed protein | Unknown, Unknown | gi|307104059 |
| 19,035.7/7.02 | 1 | 28 |
| D50 | Aspartate carbamoyltransferase | Enzyme of the first committed step in pyrimidine synthesis, Protein activity regulation | P49077 |
| 43,139.3/6.21 | 8 | 55 |
| D51 | Hypothetical protein CHLNCDRAFT_35404 | Protein serine/threonine kinase, Protein fate (folding, modification, destination) | gi|307107220 |
| 40,979.4/9.01 | 6 | 56 |
| D53 | Hypothetical protein CHLNCDRAFT_52952 | Calcium ion binding, Protein with binding function or cofactor requirement | gi|307106250 |
| 245,122.6/7.28 | 1 | 27 |
| D54 | 14-3-3-like protein | Multifunctional chaperone, posttranslational modification, Protein with binding function or cofactor requirement | P52908 |
| 29,495.8/4.9 | 1 | 32 |
| D60 | Elongation factor 2 (EF-2) | Catalyze GTP dependent ribosomal translocation step during translation elongation, Protein with binding function or cofactor requirement | gi|119167 |
| 94,054.8/5.84 | 17 | 308 |
| D65 | Expressed protein | Splicing coactivator, RNA processing, Transcription | gi|307109910 |
| 84,395.1/10.28 | 1 | 28 |
| D69 | Citrate synthase | Citrate synthesis, located in mitochondria, Energy | gi|307105555 |
| 53,533.7/7.24 | 5 | 98 |
| D72 | Hypothetical protein CHLNCDRAFT_56456 | Dystonin, growth -arrest-specific protein, cytoskeletone, Subcellular localization | gi|307111694 |
| 311,562.1/4.77 | 8 | 66 |
| D73 | Ribosomal protein | Large ribosomal subunit, Protein synthesis | gi|307103203 |
| 25,401/8.65 | 10 | 138 |
| D80 | Hypothetical protein CHLNCDRAFT_138729 | Electron transport, Protein with binding function or cofactor requirement | gi|307104457 |
| 62,588.1/9.52 | 11 | 53 |
| D82 | OSJNBb0032E06.9 | Ribonuclease H activity, Cell cycle and DNA processing | gi|38344375 |
| 138,142.2/8.96 | 15 | 83 |
| D83 | Protein W01F3.3a (mlt-11) | Serine-type endopeptidase inhibitor activity, Development | gi|115534910 |
| 236,516.9/5.07 | 10 | 84 |
| D86 | Fumarate hydratase | Catalyze S-malate synthesis, mitochondria | gi|17549498 |
| 49,372.3/6.07 | 4 | 127 |
| D89 | Ribulose bisphosphate carboxylase small chain 1 | Carbon dioxide fixation, Energy | P00873 |
| 20,606.4/9.36 | 2 | 66 |
|
| |||||||
| U1 | Chloroplast thioredoxin peroxidase | Peroxidase activity, Cell rescue, defense and virulence | gi|294845922 |
| 17,421/5.15 | 2 | 193 |
| U2 | SMC domain protein | Chromosome structure maintenance, Unknown | gi|296427824 |
| 65,238/5.63 | 87 | |
| U3 | Peroxiredoxin TSA1 | Oxidoreductase, cell redox homeostasis, Cell rescue, defense and virulence | gi|126132194 |
| 21,761/4.92 | 2 | 82 |
| U4 | Magnesium chelatase subunit of protochlorophyllide reductase | Chlorophyll biosynthesis, Protein with binding function or cofactor requirement | gi|254798626 |
| 39,567/5.08 | 6 | 310 |
| U5 | 2-Cys peroxiredoxin | Oxidoreductase, cell redox homeostasis, Cell rescue, defense and virulence | gi|327506370 |
| 22,235/5.74 | 1 | 51 |
| U6 | Hypothetical protein CHLNCDRAFT_48133 | Ornithine carbamoyltransferase, Protein with binding function or cofactor requirement | gi|307109894 |
| 38,764.5/6.68 | 9 | 51 |
| U7 | Hypothetical protein CHLNCDRAFT_53139 | Antioxidant activity, Cell rescue, defense and virulence | gi|307106076 |
| 21,778.9/8.35 | 1 | 40 |
| U8 | Hypothetical protein BAL199_15803 | Unknown, Unknown | gi|163792326 |
| 42,102.3/5.49 | 12 | 88 |
| U9 | Hypothetical protein CHLNCDRAFT_48477 | Membrane transport, Cellular transport, transport facilitation and transport routes | gi|307110872 |
| 31,637.3/9.49 | 1 | 29 |
| U10 | tRNA(Ile)-lysidine synthase, chloroplastic | Ligase activity, translation, Transcription | Q32RX0 |
| 58,797/10.16 | 1 | 29 |
| U11 | Penecillin-binding protein 2 | Penicillin binding, Protein with binding function or cofactor requirement | gi|163752395 |
| 68,820.33/9.54 | 67 | |
| U12 | Aldehyde dehydrogenase | Oxidation of aldehyde, Metabolism | gi|285018869 |
| 54,004.7/6.05 | 64 | |
| U13 | Hypothetical protein CHLNCDRAFT_30965 | Structural constitute of ribosome, Protein synthesis | gi|307107744 |
| 21,281.2/10.33 | 8 | 51 |
| U14 | Hypothetical protein CHLNCDRAFT_143237 | Dystonin, growth arrest specific protein, Subcelluar location | gi|307109339 |
| 56,981.7/5.56 | 13 | 53 |
| U15 | FG-GAP repeat protein | Ligand binding, Unknown | gi|40062562 |
| 136,477.9/4.18 | 66 | |
| U16 | Expressed protein | Unknown, Unknown | gi|307111048 |
| 20,888.8/10.28 | 6 | 57 |
| U17 | Hypothetical protein CHLNCDRAFT_59525 | nuclear receptor binding factor-1, Cell rescue, defense and virulence | gi|307111650 |
| 34,897.1/5.06 | 68 | |
| U18 | Hypothetical protein PEPMIC_01485 | Unknown, Unknown | gi|160947550 |
| 18,170.3/4.67 | 7 | 83 |
| U19 | Hypothetical protein CHLNCDRAFT_58231 | Ribosomal protein L22, Protein synthesis | gi|307105888 |
| 67,650.2/10.05 | 1 | 29 |
| U20 | C protein alpha-antigen | Receptor, Protein with binding function or cofactor requirement | gi|307708369 |
| 34,6246.9/4.98 | 65 | |
| U21 | 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase | Oxidoreductase, terpenoids biosynthesis, Protein with binding function or cofactor requirement | Q5QYA9 |
| 40,462/5.68 | 1 | 58 |
| U22 | N-(5’-phosphoribosyl)anthranilate isomerase | Tryptophan biosynthesis, Metabolism | gi|307107003 |
| 20,906.8/5.55 | 1 | 31 |
| U23 | Hypothetical protein CHLNCDRAFT_37743 | Aldehyde dehydrogenase, Metabolism | gi|307102335 |
| 45,285.3/6.11 | 3 | 111 |
| U24 | Hypothetical protein OsI_036678 | Calcium ion binding, Protein with binding function or cofactor requirement | gi|125536231 |
| 31,743.5/9.98 | 10 | 93 |
| U25 | Chloroplast 30S ribosomal protein S4 | Structural constituent of ribosome, Protein synthesis | P59137 |
| 23,589.9/10.3 | 1 | 30 |
| U26 | Hypothetical protein CHLNCDRAFT_140182 | Transcription initiation factor, Transcription | gi|307103188 |
| 63,894.8/5.19 | 13 | 54 |
| U27 | Nitrate reductase [NADH] 1 | Catalyze nitrite synthesis, Metabolism | P16081 |
| 101,447.9/6.19 | 1 | 29 |
| U28 | Ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit | Carbon fixation, Energy | gi|164455027 |
| 52,496.3/5.99 | 1 | 32 |
| U29 | Hypothetical protein MGG_08723 | Unknown, Unknown | gi|145601241 |
| 36,967.8/5.69 | 8 | 83 |
| U30 | Expressed protein | Large subunit of ribosome, Protein synthesis | gi|307108236 |
| 9805.4/11.71 | 4 | 69 |
| U31 | Hypothetical protein CHLNCDRAFT_59740 | 3-oxoacyl-(acyl-carrier-protein) synthase, lipid transport, Cellular transport, transport facilitation and transport routes | gi|307104988 |
| 32,230.3/6.19 | 1 | 28 |
| U32 | Hypothetical protein CHLNCDRAFT_18194 | Unknown, Unknown | gi|307111928 |
| 9084.4/4.37 | 1 | 28 |
| U33 | Ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit | Carbon fixation, Energy | gi|164455037 |
| 52,496.3/6.0 | 18 | 193 |
| U34 | Glucose-6-phosphate isomerase | Isomerase, involved in glycolysis, Energy | gi|284434863 |
| 27,035/5.35 | 1 | 48 |
| U35 | Hypothetical protein CHLNCDRAFT_143799 | Unknown, Unknown | gi|307108818 |
| 43,154.4/9.57 | 1 | 27 |
| U36 | Superoxide dismutase | Antioxidant enzyme, Cellular communication/signal transduction mechanism | gi|34558145 |
| 25,795.1/8.89 | 78 | |
| U37 | Hypothetical protein CHLNCDRAFT_138879 | FAP-dependent helicase activity, Transcription | gi|307104244 |
| 59,382.6/9.77 | 1 | 27 |
| U38 | Glucose -6-phosphate isomerase | Glycolysis enzyme, Energy | gi|307105594 |
| 72,048.5/6.41 | 7 | 53 |
| U39 | GTP-binding protein | Intracellular protein transport, Cellular communication/signal transduction mechanism | gi|307106020 |
| 25,468.9/6.66 | 2 | 66 |
All the down-regulated protein spots were labeled as Dn. The up-regulated protein spots were labeled as Un. Down-regulation means a decreased protein expression when the test group (after inhibitor treatment) was compared to the control group. Up-regulation means an increased protein expression when the test group was compared to the control group. a refers to the number in Figure 4. b protein name from NCBI Nr and Swiss-prot database. c function of hypothetical proteins is described according to the GO (gene ontology) information. d accession number from NCBI Nr database or Swiss-prot database. e species name from NCBI Nr and Swiss-prot database. f number of peptides used for the protein identification, those proteins with no peptides number listed were identified through de novo sequencing and MS-BLAST search against nrdb95 database. g score is defined as −10 × Log (P), where P is the absolute possibility and is closely related the size of database used for searching and automatically calculated by the MASCOT search engine. The minimal threshold value was 25. For the MS-Blast identification, the score meant the HSPs. MW, molecular weight.
Variation in F.D. of up-regulated and down-regulated proteins following SHAM, antimycin A and NaN3 treatment.
| Spot a | F.D. h | ||
|---|---|---|---|
| SHAM | Antimycin A | NaN3 | |
| Down-regulated proteins | |||
| D2 | −4.95 ± 0.58 | −5.27 ± 2.16 | |
| D3 | −6.57 ± 0.59 | ||
| D4 | −3.01 ± 0.11 | −2.37 ± 0.22 | −2.29 ± 0.86 |
| D5 | −2.22 ± 0.30 | −1.93 ± 0.20 | |
| D6 | −2.18 ± 0.11 | ||
| D9 | −1.81 ± 0.35 | ||
| D10 | −1.77 ± 0.35 | ||
| D12 | −2.37 ± 0.74 | −3.12 ± 0.05 | |
| D14 | −1.95 ± 0.20 | −1.98 ± 0.43 | −2.29 ± 0.59 |
| D15 | −2.27 ± 0.66 | −6.95 ± 2.48 | |
| D17 | −2.45 ± 0.98 | −4.46 ± 1.59 | −3.87 ± 0.79 |
| D19 | −2.42 ± 0.98 | −2.08 ± 0.25 | |
| D21 | −2.26 ± 0.82 | ||
| D22 | −1.87 ± 0.26 | −6.32 ± 1.36 | −1.87 ± 0.26 |
| D25 | >−100 | >−100 | |
| D30 | >−100 | >−100 | |
| D36 | −3.03 ± 1.22 | −3.08 ± 0.91 | |
| D37 | −3.32 ± 0.65 | −5.66 ± 0.04 | |
| D39 | −2.27 ± 0.57 | ||
| D40 | >−100 | >−100 | |
| D45 | −2.03 ± 0.02 | ||
| D46 | −1.77 ± 0.37 | ||
| D50 | −1.98 ± 0.14 | ||
| D51 | −1.65 ± 0.24 | ||
| D53 | −1.89 ± 0.46 | −1.89 ± 0.46 | |
| D54 | −1.85 ± 0.33 | ||
| D60 | >−100 | ||
| D65 | >−100 | ||
| D69 | −3.55 ± 0.81 | ||
| D72 | −2.54 ± 0.97 | ||
| D73 | −4.20 ± 1.37 | ||
| D80 | −2.24 ± 0.52 | ||
| D82 | −1.89 ± 0.25 | ||
| D83 | −1.89 ± 0.30 | ||
| D86 | −1.59 ± 0.20 | ||
| D89 | −1.76 ± 0.38 | ||
| Up-regulated proteins | |||
| U1 | 1.65 ± 0.57 | ||
| U2 | 1.72 ± 0.48 | ||
| U3 | 1.53 ± 0.16 | 1.62 ± 0.08 | |
| U4 | 1.60 ± 0.09 | ||
| U5 | 1.84 ± 0.37 | ||
| U6 | 1.92 ± 0.46 | ||
| U7 | 1.85 ± 0.33 | ||
| U8 | 1.65 ± 0.57 | 1.59 ± 0.28 | 1.94 ± 0.68 |
| U9 | 1.54 ± 0.18 | ||
| U10 | 2.13 ± 0.37 | 2.75 ± 0.02 | |
| U11 | 1.68 ± 0.30 | ||
| U12 | 2.53 ± 0.78 | ||
| U13 | 2.56 ± 0.73 | 3.96 ± 2.05 | |
| U14 | 2.18 ± 0.10 | ||
| U15 | 3.08 ± 1.38 | ||
| U16 | 2.66 ± 0.45 | ||
| U17 | 2.21 ± 0.25 | ||
| U18 | 3.46 ± 0.93 | ||
| U19 | 4.38 ± 1.02 | ||
| U20 | 4.05 ± 0.09 | ||
| U21 | 5.36 ± 0.05 | 3.75 ± 0.01 | 1.53 ± 0.21 |
| U22 | 6.89 ± 1.10 | 3.61 ± 0.86 | |
| U23 | >100.00 | 5.39 ± 0.69 | |
| U24 | >100.00 | ||
| U25 | 1.79 ± 0.53 | 1.89 ± 0.39 | |
| U26 | 1.77 ± 0.39 | ||
| U27 | 1.60 ± 0.05 | ||
| U28 | 1.92 ± 0.48 | ||
| U29 | 1.92 ± 0.44 | ||
| U30 | 2.36 ± 0.71 | ||
| U31 | 2.56 ± 0.75 | ||
| U32 | 2.16 ± 1.08 | ||
| U33 | 3.02 ± 0.08 | ||
| U34 | >100 | ||
| U35 | 1.75 ± 0.21 | ||
| U36 | 1.60 ± 0.03 | ||
| U37 | 2.33 ± 0.20 | ||
| U38 | >100 | ||
| U39 | 3.75 ± 0.01 | ||
All the down-regulated protein spots were labeled ash Dn. The up-regulated protein spots were labeled as Un. a refers to the number in Figure 4. h fold difference (F.D.) is used to describe the protein expression level variation following inhibitors treatment compared with the control and expressed as mean ± S.D. from three independent experiments. Positive values mean up-regulation and negative values mean down-regulation.
Figure 5An overview of the metabolic pathways of C. pyrenoidosa and the interactions between the identified up- or down-regulated proteins. Antioxidant proteins are displayed in the mitochondria. The chloroplast proteins are displayed in chlorophyll and lutein biosynthesis. Transcription and protein fate-related proteins are displayed in the signaling from cytoplasm to nucleus. Metabolism and energy-related proteins are displayed in glycolysis and gluconeogenesis pathways. ALA, 5-aminolevulinic acid; DXP, 1-deoxy-d-xylulose 5-phosphate; 1,3-DPG, 1,3-diphosphoglycerate; EMP, glycolytic pathway; GPI, Glucose-6-phosphate; G3P, glyceraldehyde-3-phosphate; HMBPP, 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate; ME-cPP, 2-C-methyl-d-erythritol-2,4-cyclodiphosphate; mRET, mitochondrial respiratory electron transport chain; MEP Pathway, methylerythritol phosphate pathway; OAA, oxaloacetic acid; PEP, phosphoenolpyruvate; PIF, phytochrome-interacting factor; Pfr, active form; Spot U3, peroxiredoxin TSA1; Spot U4, Magnesium chelatase subunit of protochlorophyllide reductase (ChlI); Spot U5, 2-Cys peroxiredoxin; Spot D14, coproporphyrinogen III oxidase; Spot D17, d-3-phosphoglycerate dehydrogenase; Spot U21, 4-hydroxy-3-methylbut-2-en-1yl diphosphate synthase (ispG); Spot D25, Phytochrome A; Spot D30, TCP-1 eta subunit (CCT7); Spot U36, Superoxide dismutase; Spot D37, phosphoenolpyruvate carboxykinase (PEPCK). The solid line box indicates that the metabolic pathway has been verified, and the dashed box indicates that it needs to be verified. The “→” indicates that the reaction is completed in one step, and the “→∙∙∙→” indicates that the multi-step reactions are required.